Evidence map›Paper›PMID 28325294›Full record

ArticleMolecular therapy. Nucleic acids2017

Therapeutic Effect of Novel Single-Stranded RNAi Agent Targeting Periostin in Eyes with Retinal Neovascularization.

Takahito Nakama, Shigeo Yoshida, Keijiro Ishikawa, Yuki Kubo, Yoshiyuki Kobayashi, Yedi Zhou, Shintaro Nakao, Toshio Hisatomi, Yasuhiro Ikeda, Kazumasa Takao and 8 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Increased expression of periostin and tenascin-C in eyes with neovascular glaucoma secondary to PDR.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Periostin function in communication with extracellular matrices.Journal of cell communication and signaling · 2018
    Review
  11. Review
  12. Periostin in vitreoretinal diseases.Cellular and molecular life sciences : CMLS · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Takahito NakamaDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Shigeo YoshidaDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan. Electronic address: yosida@eye.med.kyushu-u.ac.jp.
Keijiro IshikawaDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Yuki KuboDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Yoshiyuki KobayashiDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Yedi ZhouDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Shintaro NakaoDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Toshio HisatomiDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Yasuhiro IkedaDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Kazumasa TakaoAQUA Therapeutics Co., Ltd., Kobe 650-0035, Japan.
Kazunori YoshikawaAQUA Therapeutics Co., Ltd., Kobe 650-0035, Japan.
Akira MatsudaDepartment of Ophthalmology, Juntendo University School of Medicine, Tokyo 113-8421, Japan.
Junya OnoShino-test Corporation, Sagamihara 252-0331, Japan.
Shoichiro OhtaDivision of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga 849-8501, Japan.
Kenji IzuharaDivision of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga 849-8501, Japan.
Akira KudoDepartment of Biological Information, Tokyo Institute of Technology, Yokohama 226-8501, Japan.
Koh-Hei SonodaDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Tatsuro IshibashiDepartment of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Kyushu University · JPSaga Medical School Hospital · JPJuntendo University · JPShino-Test CorporationTokyo Institute of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal neovascularization (NV) due to retinal ischemia remains one of the principal causes of vision impairment in patients with ischemic retinal diseases. We recently reported that periostin (POSTN) may play a role in the development of preretinal fibrovascular membranes, but its role in retinal NV has not been determined. The purpose of this study was to examine the expression of POSTN in the ischemic retinas of a mouse model of oxygen-induced retinal NV. We also studied the function of POSTN on retinal NV using Postn KO mice and human retinal endothelial cells (HRECs) in culture. In addition, we used a novel RNAi agent, NK0144, which targets POSTN to determine its effect on the development of retinal NV. Our results showed that the expression of POSTN was increased in the vascular endothelial cells, pericytes, and M2 macrophages in ischemic retinas. POSTN promoted the ischemia-induced retinal NV by Akt phosphorylation through integrin αvβ3. NK0144 had a greater inhibitory effect than canonical double-stranded siRNA on preretinal pathological NV in vivo and in vitro. These findings suggest a causal relationship between POSTN and retinal NV, and indicate a potential therapeutic role of intravitreal injection of NK0144 for retinal neovascular diseases.

Indexed as

diabetic retinopathyneovascularizationperiostinRNAi

Identifiers

PMID28325294
PMCPMC5363510
OpenAlexW2586528843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.